CONCEPT OF SOLUBLE RECEPTORS IN BRONCHIAL ASTHMA

Abstract

The functioning of soluble receptors, mainly soluble cytokine receptors, has been of interest to researchers since the last decade of the 20th century. Allergists’ interest in the problem of soluble receptors is related to our research into the pathogenesis of bronchial asthma (BA), specifically the development of ectopic chemosensory signaling systems, including ectopic bitter taste receptors Tas2R, and signaling pathways of the Receptor for Advanced Glycation Endproducts (RAGE). The expression of soluble receptors in BA was investigated in both studies. The article discusses the mechanisms of soluble receptor formation: 1) proteolytic cleavage of existing membrane receptors, 2) synthesis and release of soluble receptors lacking a transmembrane domain via alternative mRNA splicing, 3) release of membrane receptors in exosomes. Possible functional effects of soluble receptors are considered: neutralization of corresponding ligands (decoy receptors), ligand transport, ligand stabilization, and binding of membrane proteins. The results of studies of soluble receptors in health and disease are sometimes contradictory and not fully understood. Soluble receptors may represent promising therapeutic agents. Our previous data on the possible function of a number of soluble receptors: Tas2R38, Tas2R31, Tas2R5 in the study of patients with asthma are considered from the already known positions of the soluble receptors functioning.The most important characteristics of the soluble receptors studied in BA are: 1) lower plasma levels of all discussed Tas2Rs in allergic asthma compared to non-allergic; 2) inverse correlation between plasma Tas2R levels and bronchial resistance; 3) correlation of Tas2Rs with monocyte-macrophage cells, granulocytes and bronchial ciliated cells. The regulatory role of soluble receptors involved in asthma pathogenesis, mainly cytokines, as well as sTas2R and sRAGE, can be viewed through the corresponding membrane receptor functions. In this case, soluble forms of receptors play the role of decoy proteins that block functions mediated by membrane receptors. In this approach, in BA, the discussed soluble cytokine receptors and sRAGE have a positive regulatory effect, while sTas2R have a negative one. The balance of soluble and membrane-bound receptor functions in cells involved in asthma pathogenesis is crucial for developing potentially new targeted therapies for asthma, where Tas2R and RAGE receptors are the target.

1. Симбирцев А.С. Иммунофармакологические аспекты системы цитокинов. Бюллетень сибирской медицины. 2019; 18 (1): 84–95. https://doi.org: 10.20538/1682-0363-2019-1-84–95. Simbirtsev A.S. Immunopharmacological aspects of the cytokine system. Bulletin of Siberian Medicine. 2019; 18 (1): 84–95. https://doi.org: 10.20538/1682-0363-2019-1-84–95.

2. Минеев В.Н., Трофимов В.И., Нёма М.А., Кузикова А.А. Вкусовые рецепторы к горькому вкусу в сыворотке крови при бронхиальной астме (гипотеза). Пульмонология. 2017;27(5):567-572. doi.org/10.18093/0869-0189-2017-27-5-567-572. Mineev V.N., Trofimov V.I., Nyoma M.A., Kuzikova A.A. Bitter taste receptors in serum of patients with asthma (a hypothesis). Pulmonologiya. 2017:27(5):567-572. (in Russ.) doi.org/10.18093/0869-0189-2017-27-5-567-572

3. Минеев В.Н., Нёма М.А., Трофимов В.И. Эктопические вкусовые рецепторы TAS2R31 в сыворотке крови при различных вариантах бронхиальной астмы. Тихоокеанский медицинский журнал. 2021;1:68–71. doi: 10.34215/1609-1175-2021-1-68-71 Mineev VN, Nyoma MA, Trofimov VI. Ectopic taste buds TAS2R31 in blood serum in different types of bronchial asthma. Pacific Medical Journal. 2021;1:68–71 (in Russ). doi: 10.34215/1609-1175-2021-1-68-71.

4. Нёма М.А., Минеев В.Н., Муркина Р.Г., Садовая В.В. Ассоциация плазменных уровней эктопического вкусового рецептора TAS2R5 с клинико-функциональными характеристиками бронхиальной астмы. University Therapeutic Journal. 2025;7(2):84–92. doi: doi.org/10.56871/UTJ.2025.77.75.007. Nyoma MA, Mineev VN, Murkina RG, Sadovaya VV. Association of plasma levels of the TAS2R5 ectopic taste receptor with clinical and functional characteristics of bronchial asthma. University Therapeutic Journal. 2025;7(2):84–92. doi: doi.org/10.56871/UTJ.2025.77.75.007

5. Сорокина Л.Н., Минеев В.Н., Павлова А.С., Трофимов В.И. Роль рецептора к конечным продуктами гликирования (RAGE) в патогенезе бронхиальной астмы. Пульмонология. 2025;35(1):95–101. doi: 10.18093/0869-0189-2025-35-1-95-101. Sorokina L.N., Mineev V.N., Pavlova A.S., Trofimov V.I. The role of the receptor for advanced glycation endproducts (RAGE) in the pathogenesis of asthma. Pul’monologiya, 2025;35(1):95–101 (in Russ.). doi: 10.18093/0869-0189-2025-35-1-95-101

6. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson, D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172–3177.

7. Levine S.J. Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem. 2008;283(21):14177-81. doi: 10.1074/jbc.R700052200

8. Heaney ML, Golde DW. Soluble receptors in human disease. J Leukoc Biol. 1998 Aug;64(2):135-46. doi: 10.1002/jlb.64.2.135.

9. Kefaloyianni E. Soluble forms of cytokine and growth factor receptors: mechanisms of generation and modes of action in the regulation of local and systemic inflammation. FEBS Lett. 2022;596(5):589-606. doi: 10.1002/1873-3468.14305.

10. Lokau J, Garbers C. Biological functions and therapeutic opportunities of soluble cytokine receptors. Cytokine Growth Factor Rev. 2020;55:94-108. doi: 10.1016/j.cytogfr.2020.04.003.

11. Минеев В.Н., Сорокина Л.Н. Феномен гликирования белков при бронхиальной астме. Университетский терапевтический вестник. 2023;5(4):73–81. doi.org/10.56871/UTJ.2023.73.75.006. Mineev VN, Sorokina LN. Protein glycation phenomenon in bronchial asthma. University therapeutic journal (St. Petersburg). 2023;5(4):73-81. doi.org/10.56871/UTJ.2023.73.75.006

12. Кетлинский, С. А. Цитокины. / С. А. Кетлинский, А. С. Симбирцев. — СПб : Фолиант, 2008. — 552 с. [Ketlinsky, S. A. Cytokines. / S. A. Ketlinsky, A. S. Simbirtsev. - St. Petersburg: Foliant, 2008. - 552 p.]

13. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151(3):1548-1561.

14. Cameron L, Christodoulopoulos P, Lavigne F, Nakamura Y, Eidelman D, McEuen A, Walls A, Tavernier J, Minshall E, Moqbel R, Hamid Q. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J Immunol. 2000;164(3):1538-1545. doi: 10.4049/jimmunol.164.3.1538.

15. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007 Sep 7;282(36):26369-80. doi: 10.1074/jbc.M704916200.

16. Crawley AM, Faucher S, Angel JB. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol. 2010 May 1;184(9):4679-87. doi: 10.4049/jimmunol.0903758.

17. Минеев В.Н., Сорокина Л.Н., Трофимов В.И., Нёма М.А., Иванов В.А. Рецепторы к интерлейкину-4 и -13: строение, функция и генетический полиморфизм. Пульмонология. 2010;(3):113-119. https://doi.org/10.18093/0869-0189-2010-3-113-119

18. Schumertl T, Lokau J, Rose-John S, Garbers C. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease. Biochim Biophys Acta Mol Cell Res. 2022;1869(1):119143. doi: 10.1016/j.bbamcr.2021.119143.

19. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992;175(2):323-329. doi: 10.1084/jem.175.2.323.

20. Lundström W, Highfill S, Walsh ST, Beq S, Morse E, Kockum I, Alfredsson L, Olsson T, Hillert J, Mackall CL. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A. 2013;110(19):E1761-70. doi: 10.1073/pnas.1222303110.

21. Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol. 1993;150(7):2717-2723.

22. Eissner G, Kirchner S, Lindner H, Kolch W, Janosch P, Grell M, Scheurich P, Andreesen R, Holler E. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol. 2000 Jun 15;164(12):6193-8. doi: 10.4049/jimmunol.164.12.6193.

23. Zhang H, Deng T, Liu R, Bai M, Zhou L, Wang X, Li S, Wang X, Yang H, Li J, Ning T, Huang D, Li H, Zhang L, Ying G, Ba Y. Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat Commun. 2017;8:15016. doi: 10.1038/ncomms15016. Erratum in: Nat Commun. 2023;14(1):1700.

24. Виткина Т. И., Сидлецкая К. А. Роль интерлейкин-6 сигналинга в развитии системного воспаления при хронической обструктивной болезни легких. Бюллетень физиологии и патологии дыхания. 2018;(69): 97-106. doi: doi.org/10.12737/article_5b9858ead1b5e3.93619630

25. Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 2001;22(6):328-36. doi: 10.1016/s1471-4906(01)01941-x.

26. Bien E, Balcerska A. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers. 2008;13(1):1-26. doi: 10.1080/13547500701674063.

27. Maier LM, Anderson DE, Severson CA, Baecher-Allan C, Healy B, Liu DV, Wittrup KD, De Jager PL, Hafler DA. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol. 2009;182(3):1541-1547. doi: 10.4049/jimmunol.182.3.1541.

28. Silvestri T, Pulsatelli L, Dolzani P, Facchini A, Meliconi R. Elevated serum levels of soluble interleukin-4 receptor in osteoarthritis. Osteoarthritis Cartilage. 2006;14(7):717-9. doi: 10.1016/j.joca.2006.02.015.

29. Hytönen AM, Löwhagen O, Arvidsson M, Balder B, Björk AL, Lindgren S, Hahn-Zoric M, Hanson LA, Padyukov L. Haplotypes of the interleukin-4 receptor alpha chain gene associate with susceptibility to and severity of atopic asthma. Clin Exp Allergy. 2004;34(10):1570-1575. doi: 10.1111/j.1365-2222.2004.02069.x.

30. Wilson TM, Maric I, Shukla J, Brown M, Santos C, Simakova O, Khoury P, Fay MP, Kozhich A, Kolbeck R, Metcalfe DD, Klion AD. IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis. J Allergy Clin Immunol. 2011 Nov;128(5):1086-92.e1-3. doi: 10.1016/j.jaci.2011.05.032.

31. Vallejo-Vaz AJ. Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2. Eur Cardiol. 2015;10(1):37-41. doi: 10.15420/ecr.2015.10.01.37.

32. Bae E, Cha RH, Kim YC, An JN, Kim DK, Yoo KD, Lee SM, Kim MH, Park JT, Kang SW, Park JY, Lim CS, Kim YS, Yang SH, Lee JP. Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. Medicine (Baltimore). 2017;96(19):e6666. doi: 10.1097/MD.0000000000006666.

33. Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, Mayadas TN, Warram JH, Krolewski AS. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012;23(3):516-24. doi: 10.1681/ASN.2011060628.

34. Сигидин Я.А., Лукина Г.В. Препарат этанерцептв современной ревматологии. Научно-практическая ревматология. 2010;48(3):78-82. doi.org/10.14412/1995-4484-2010-447 . Sigidin Ya.A., Lukina G.V. Preparat etanertseptv sovremennoy revmatologii. Rheumatology Science and Practice. 2010;48(3):78-82. (In Russ.) doi.org/10.14412/1995-4484-2010-447

35. Гусев Е.Ю., Зотова Н.В., Журавлева Ю.А., Черешнев В.А. Физиологическая и патогенетическая роль рецепторов-мусорщиков у человека. Медицинская иммунология. 2020; 22 (1): 7–48. DOI:10.15789/1563-0625-PAP-1893. Gusev E.Yu., Zotova N.V., Zhuravleva Yu.A., Chereshnev V.A. Physiological and pathogenic role of scavenger receptors in humans. Medical Immunology (Russia)/Meditsinskaya Immunologiya, 2020, Vol. 22, no. 1, pp. 7-48. doi: 10.15789/1563-0625-PAP-1893

36. Минеев В.Н. Эктопические обонятельные рецепторы в респираторной системе. Пульмонология. 2019;29(6):734-738. doi.org/10.18093/0869-0189-2019-29-6-734-738 . Mineev V.N. Ectopic olfactory receptors in the respiratory system. Pulmonologiya. 2019;29(6):734-738. (In Russ.) doi.org/10.18093/0869-0189-2019-29-6-734-738

37. Минеев В.Н. Эктопические фоторецепторы при бронхиальной астме: возможная патогенетическая роль. Иммунопатология, аллергол, инфектол. 2020; 2:34-40. doi: 10.14427/jipai.2020.2.34. Mineev V.N. Ectopic photoreceptors in bronchial asthma: possible pathogenetic role. Immunopathology, allergology, infectology 2020; 2:34-40. doi: 10.14427/jipai.2020.2.34

38. Ekoff M., Choi J.H., James A., Dahlén B., Nilsson G., Dahlén S.E. Bitter taste receptor (TAS2R) agonists inhibit IgE-dependent mast cell activation. J Allergy Clin Immunol. 2014;134(2):475-8. doi: 10.1016/j.jaci.2014.02.029.

39. Tong A, Yang H, Yu X, Wang D, Guan J, Zhao M, Li J. Mechanisms and novel therapeutic roles of bitter taste receptors in diseases. Theranostics. 2025;15(9):3961-3978. doi: 10.7150/thno.107406.

40. Orsmark-Pietras C., James A., Konradsen J.R., Nordlund B., Söderhäll C., Pulkkinen V., Pedroletti C., Daham K., Kupczyk M., Dahlén B., Kere J., Dahlén S.E., Hedlin G., Melén E. Transcriptome analysis reveals upregulation of bitter taste receptors in severe asthmatics. Eur Respir J. 2013;42(1):65-78. doi: 10.1183/09031936.00077712.

41. Milutinovic PS, Alcorn JF, Englert JM, Crum LT, Oury TD. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am J Pathol. 2012;181(4):1215-25. doi: 10.1016/j.ajpath.2012.06.031

42. Новиков В.В. Растворимые дифференцировочные молекулы при воспалительных процессах (Вторая жизнь белков): монография / Новиков В.В. - Нижний Новгород: Гладкова О.В. “Издательский салон”, 2022. - 212 с. Novikov V.V. Soluble Differentiation Molecules in Inflammatory Processes (The Second Life of Proteins): Monograph / Novikov V.V. - Nizhny Novgorod: Gladkova O.V. “Publishing Salon”, 2022. - 212 p.